At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
Location: France, Bourgogne-Franche-Comté, Dijon
Member count: 11-50
Total raised: $26.888376M
Founded date: 2016
Investors 4
| Date | Name | Website |
| 10.08.2023 | Crescent E... | crescenten... |
| - | Auriga Par... | auriga.vc |
| - | Capital Gr... | capitalgra... |
| - | Elaia Part... | elaia.com |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 20.07.2023 | Series A | $26.888376... | - | vcbay.news... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 20.07.2023 | Exeliom Biosciences Raises Additional €8M; Closes €24M Serie... | Exeliom Biosciences, a Paris, and Dijon, France-based clinical-stage biopharmaceutical company, rais... | finsmes.co... |
| 04.07.2023 | Exeliom Bioscience closes Series A financing at EUR 24 milli... | Paris, France-based clinical-stage biopharmaceutical company specialized in the development of micro... | vcbay.news... |
| 03.07.2023 | Paris-based Exeliom Biosciences completes final close of €24... | - | eu-startup... |
| - | Exeliom Biosciences | “At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential... | fastfounde... |